AO-176 is an anti-CD47 monoclonal antibody currently being developed for patients with multiple myeloma and select solid tumors. Arch Oncology is evaluating this therapy both as a monotherapy and in combination with standard therapies.
| SparkCures ID | 391 |
|---|---|
| Developed By | Arch Oncology |
| Generic Name | AO-176 |
| Treatment Classifications | |
| Treatment Targets |
SparkCures is working closely with Arch Oncology to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.
Learn more about how we work with industry partners